Insider Buys Gossamer Bio Shares as NDA Filing Sparks Growth Hope

Insider Buying Signals a Strong Commitment to the New‑Drug Push

On September 23, 2026, Daniel Thomas O., a member of the board of directors of Gossamer Bio, exercised a stock‑option grant for 10,000 shares at an exercise price of $0.00, adding those shares to his post‑transaction holding. The transaction occurred only days after the company filed its first New Drug Application (NDA) for seralutinib, its Phase 3 lead product intended to treat pulmonary arterial hypertension. Although the option’s exercise price is zero—a common feature of internal grants—Thomas’s action signals strong confidence that the company’s valuation will rise once the FDA accepts the application and the drug ultimately reaches the market.

Implications for Shareholders

Gossamer’s current market capitalization stands at $67.2 million, while its price‑earnings ratio is a negative –0.24. These figures underscore the company’s pre‑profit status and its reliance on future product revenue streams. Thomas’s purchase indicates that insiders believe the forthcoming regulatory milestones will unlock shareholder value, potentially reversing the stock’s 21.41 % monthly decline and the 95.15 % yearly drop that have weighed on the share price. Should the FDA’s pre‑NDA meeting be followed by a favorable filing, the company’s share price could experience significant upside, particularly given the 52‑week high of $309.60 and the current low of $9.12.

Profile of Daniel Thomas O.

Thomas has a consistent track record of accumulating equity through option purchases rather than liquidating positions. In June 2026 he acquired 115,000 shares, and in September he added another 10,000 shares. His transactions align closely with key corporate events: the June purchase followed the company’s first‑quarter earnings release and a strategic partnership announcement, while the September purchase coincided with the NDA filing. Thomas’s preference for options—leveraging vesting schedules—reflects a long‑term alignment of interests with company performance. This disciplined approach has earned him a reputation among peers for “patient‑capital” investing in early‑stage biotechs.

Investor Takeaway

For investors, Thomas’s recent buy provides additional credibility to Gossamer’s ambitious clinical pipeline. Coupled with a spike in social‑media buzz (a +9 sentiment score and a 698 % buzz spike), the insider activity warrants a closer examination of the company’s regulatory timeline and commercial strategy. While the stock remains volatile—evidenced by its sharp annual decline and negative earnings—this strategic insider buy, together with the NDA filing, could signal a turning point. Investors willing to tolerate short‑term price swings may view the 2026–2027 period as a potentially rewarding window, provided the FDA’s review proceeds without major setbacks.